Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome
Efficacy of Recombinant Human Clara Cell Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome
Sponsor: Baystate Medical Center
A PHASE2 clinical study on Bronchopulmonary Dysplasia and Respiratory Distress Syndrome in Premature Infant, this trial is completed. The trial is conducted by Baystate Medical Center and has accumulated 11 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2019 — Oct 2019 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Mar 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Oct 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Baystate Medical Center
- Brigham and Women's Hospital
- Instytut Centrum Zdrowia Matki Polki Klinika Neonatologii
- Poznan University of Medical Sciences
- SP ZOZ Szpital Uniwersytecki w Krakowie Oddizat Neonatologii
- Therabron Therapeutics, Inc.
- Tufts Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .